https://scholars.lib.ntu.edu.tw/handle/123456789/537916
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | HUNG-CHIH YANG | en_US |
dc.contributor.author | Tsou H.-H | en_US |
dc.contributor.author | Pei S.-N | en_US |
dc.contributor.author | Chang C.-S | en_US |
dc.contributor.author | Chen J.-H | en_US |
dc.contributor.author | MING YAO | en_US |
dc.contributor.author | Lin S.-J | en_US |
dc.contributor.author | Lin J | en_US |
dc.contributor.author | Yuan Q | en_US |
dc.contributor.author | Xia N | en_US |
dc.contributor.author | Liu T.-W | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | Taiwan Cooperative Oncology Group | en_US |
dc.date.accessioned | 2021-01-05T03:34:31Z | - |
dc.date.available | 2021-01-05T03:34:31Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046163058&doi=10.1016%2fj.jhep.2018.02.033&partnerID=40&md5=688a2222c3d0fcab04447214adc1a17d | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/537916 | - |
dc.description.abstract | Background & Aims: Absence or low anti-HBV surface antibody (anti-HBs) is associated with an increased risk of HBV reactivation in patients with lymphoma and resolved HBV infection receiving rituximab-containing chemotherapy. Quantification of anti-HBV core antibody (anti-HBc) is a new marker associated with the natural history and treatment response of chronic HBV infection. This study investigated whether baseline anti-HBc and anti-HBs levels may better predict HBV reactivation. Methods: We prospectively measured the HBV DNA levels of patients with lymphoma and resolved HBV infection receiving rituximab–cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone-based chemotherapy and started an antiviral therapy upon HBV reactivation, defined as a greater than 10-fold increase in HBV DNA compared with previous nadir levels. Anti-HBs and anti-HBc were quantified by a double-sandwich assay. Receiver-operating-characteristic-curve analysis was used to determine the optimal baseline anti-HBc/anti-HBs levels for predicting HBV reactivation. Results: HBV reactivation occurred in 24 of the 197 patients enrolled, with an incidence of 11.6/100 person-years. For the 192 patients with enough serum samples for analysis, low anti-HBs (<56.48 mIU/ml) and high anti-HBc (?6.41 IU/ml) at baseline were significantly associated with high risk of HBV reactivation (hazard ratio [HR] 8.48 and 4.52, respectively; p <0.01). The multivariate analysis indicated that (1) patients with both high anti-HBc and low anti-HBs at baseline (36 of 192 patients) had an HR of 17.29 for HBV reactivation (95% CI 3.92–76.30; p <0.001), and (2) HBV reactivation may be associated with inferior overall survival (HR 2.41; 95% CI 1.15–5.05; p = 0.02). Conclusions: Baseline anti-HBc/anti-HBs levels may predict HBV reactivation in these patients with lymphoma and help optimize prophylactic antiviral therapy for high-risk patients. Lay summary: In this study, we identified a subgroup of patients with lymphoma and resolved hepatitis B virus infection that had a high risk of hepatitis B virus reactivation after receiving rituximab-containing chemotherapy. These findings will help optimize a preventive strategy, especially in hepatitis B virus endemic regions with limited healthcare resources. Clinical trial number: NCT 00931229. ? 2018 European Association for the Study of the Liver | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.ispartof | Journal of Hepatology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; entecavir; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; virus DNA; antineoplastic agent; antivirus agent; biological marker; hepatitis B antibody; hepatitis B surface antigen; rituximab; virus DNA; adult; aged; antibody blood level; antiviral therapy; Article; cancer combination chemotherapy; cancer survival; chronic hepatitis B; clinical outcome; cohort analysis; diffuse large B cell lymphoma; disease exacerbation; female; follicular lymphoma; Hepatitis B virus; high risk patient; human; incidence; lymphoma; major clinical study; male; nonhuman; overall survival; priority journal; progression free survival; prospective study; quantitative analysis; treatment response; virus reactivation; blood; complication; hepatitis B; Hepatitis B virus; immunology; middle aged; nonhodgkin lymphoma; physiology; predictive value; procedures; risk assessment; Taiwan; virus activation; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biomarkers; DNA, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Predictive Value of Tests; Risk Assessment; Rituximab; Taiwan; Virus Activation | - |
dc.title | Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jhep.2018.02.033 | - |
dc.identifier.pmid | 29551710 | - |
dc.identifier.scopus | 2-s2.0-85046163058 | - |
dc.relation.pages | 286-292 | - |
dc.relation.journalvolume | 69 | - |
dc.relation.journalissue | 2 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Microbiology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Integrated Diagnostics and Therapeutics-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.orcid | 0000-0003-3864-9895 | - |
crisitem.author.orcid | 0000-0003-2932-0019 | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。